Study of Circulating Monocytes in Patients With Ischemic Vascular Disease
NCT04321512
Recruiting
The purpose of this research study is to discover the functions of circulating white blood cells, called monocytes, and associated circulating substances in heart attack and ischemic stroke patients. Ischemic Strokes (clots) occur as a result of an obstruction within a blood vessel supplying blood to the brain. A type of monocyte carrying a surface marker called "P2X4" helps the immune system sense and respond to danger signals from the body such as heart muscle and brain tissue injuries. The r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Myocardial Infarction, Stroke, Ischemic, Ischemia
Register for Updates
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
NCT07125729
Recruiting
This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV colorectal cancer (CRC) that can be removed by surgery (resectable). MRD testing looks for evidence of remaining tumor following treatment that is only apparent using highly sensitive techniques. There are few effective tools available outside of imaging to identify CRC pat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: CTCA at Western Regional Medical Center, Goodyear, Arizona +12 locations
Conditions: Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Register for Updates
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
NCT06319872
Recruiting
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York
Conditions: Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
Register for Updates
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207
Recruiting
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +227 locations
Conditions: Heart Failure, Systemic Inflammation
Register for Updates
Interactive Resuscitation Application for Mothers About to Experience Premature Infant Resuscitation
NCT05243043
Recruiting
The purpose of this study is to design, develop, validate and pilot test an interactive Maternal Resuscitation Navigation Application (MARINA) for the purpose of providing information and guidance about the expected events that a premature infant will experience during initial resuscitation upon delivery. This information will be shared via computer app prior to the time that the mother would be in distress due to active labor. The application will be pilot tested for functionality, usability an... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/10/2025
Locations: University of Iowa Stead Family Children's Hospital, Iowa City, Iowa
Conditions: Resuscitation
Register for Updates
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397
Recruiting
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: David Geffen School of Medicine UCLA, UCLA Health, Los Angeles, California +9 locations
Conditions: Fabry Disesase
Register for Updates
Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients
NCT05900427
Recruiting
The purpose of this trial is to compare the difference in the proportion of patients with tolerable pain scores, VAS pain scores, quality of recovery and opioid use in milligram equivalents (at 24, 48, 72, 96 and 120 hours postoperatively) in patients undergoing shoulder arthroplasty who receive interscalene blocks with or without Liposomal Bupivacaine. This is a prospective randomized, double-blinded, controlled trial that will enroll 130 subjects undergoing total shoulder arthroplasty or reve... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/10/2025
Locations: NorthShore University HealthSystem, Skokie, Illinois
Conditions: Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698
Recruiting
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study wil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: N America Res Inst - San Dimas, San Dimas, California +128 locations
Conditions: Chronic Kidney Disease
Register for Updates
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362
Recruiting
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Gender:
ALL
Ages:
Between 40 years and 84 years
Trial Updated:
08/10/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +90 locations
Conditions: Heart Failure
Register for Updates
Data Collection for Echocardiography-Based Software Assessment
NCT07126600
Recruiting
This is a prospective, observational study collecting data from routine clinical care. The information gathered will be used to support the evaluation of a software-based tool. No investigational procedures or treatments are introduced, and all data are obtained as part of standard-of-care activities.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +4 locations
Conditions: Atrial Fibrillation, Left Atrial Appendage Closure, Cardiovascular Diseases
Register for Updates
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
NCT05636176
Recruiting
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to u... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +1047 locations
Conditions: Heart Failure
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874
Recruiting
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/10/2025
Locations: Southern Cal Clinical Research, Santa Ana, California +178 locations
Conditions: Type 2 Diabetes (T2D)
Register for Updates